211 related articles for article (PubMed ID: 10672775)
1. [Reboxetine (Edronax)].
Souery D; Sternon J
Rev Med Brux; 1999 Dec; 20(6):511-6. PubMed ID: 10672775
[TBL] [Abstract][Full Text] [Related]
2. The need for new and better antidepressants: reboxetine a new option.
Dencker SJ
Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
[TBL] [Abstract][Full Text] [Related]
3. Reboxetine--another new antidepressant.
Drug Ther Bull; 1998 Nov; 36(11):86-8. PubMed ID: 10562766
[TBL] [Abstract][Full Text] [Related]
4. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
Scates AC; Doraiswamy PM
Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
[TBL] [Abstract][Full Text] [Related]
5. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Preskorn SH
J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
[No Abstract] [Full Text] [Related]
6. Reboxetine: tolerability and safety profile in patients with major depression.
Tanum L
Acta Psychiatr Scand Suppl; 2000; 402():37-40. PubMed ID: 10901157
[TBL] [Abstract][Full Text] [Related]
7. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
Kasper S; el Giamal N; Hilger E
Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
[TBL] [Abstract][Full Text] [Related]
8. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
Berzewski H; Van Moffaert M; Gagiano CA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
[TBL] [Abstract][Full Text] [Related]
10. Depersonalization-derealization syndrome induced by reboxetine.
Khazaal Y; Zullino DF
Swiss Med Wkly; 2003 Jul; 133(27-28):398-9. PubMed ID: 12947529
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
12. Noradrenaline in basic models of depression.
Leonard BE
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S11-6; discussion S71-3. PubMed ID: 9169306
[TBL] [Abstract][Full Text] [Related]
13. [SSRI resistant depression. Supplementation with noradrenergic pharmaceuticals can be a good alternative].
Bodlund O; Häggström L
Lakartidningen; 2004 Sep; 101(36):2712-4. PubMed ID: 15455633
[TBL] [Abstract][Full Text] [Related]
14. The promises and pitfalls of reboxetine.
Page ME
CNS Drug Rev; 2003; 9(4):327-42. PubMed ID: 14647527
[TBL] [Abstract][Full Text] [Related]
15. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Harkin A; Kelly JP; McNamara M; Connor TJ; Dredge K; Redmond A; Leonard BE
Eur J Pharmacol; 1999 Jan; 364(2-3):123-32. PubMed ID: 9932714
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely.
Rogóz Z; Wróbel A; Krasicka-Domka M; Maj J
Pol J Pharmacol; 1999; 51(5):399-404. PubMed ID: 10817540
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Crawford AA; Lewis S; Nutt D; Peters TJ; Cowen P; O'Donovan MC; Wiles N; Lewis G
Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
Rampello L; Alvano A; Chiechio S; Raffaele R; Vecchio I; Malaguarnera M
Arch Gerontol Geriatr; 2005; 40(3):275-85. PubMed ID: 15814161
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for a pure noradrenergic drug in the treatment of depression?
Montgomery SA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
Dannon PN; Iancu I; Grunhaus L
Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
